Ilumya has gained a US indication for adults with active psoriatic arthritis, expanding the use of an injectable medicine previously approved for plaque psoriasis. Sun Pharma announced the approval October 30, and its updated prescribing information now includes the joint disease.
The change gives patients another treatment administered by a healthcare professional. It does not establish that Ilumya works better than other approved medicines. The pivotal trials compared it with placebo, and the published results show both a benefit and limits to the response.
What the new label changes
The October prescribing information distinguishes two dosing schedules. Adults with active psoriatic arthritis and coexisting moderate-to-severe plaque psoriasis receive 100 milligrams at weeks 0 and 4, then every 12 weeks. Other adults with active psoriatic arthritis receive 100 milligrams every 12 weeks. The medicine is injected under the skin by a healthcare provider.
Patients should therefore discuss both their joint and skin disease when reviewing the schedule with their clinician. The psoriasis loading schedule should not be assumed to apply to everyone with the newly approved indication.
What the trials found
A publicly posted ACR Convergence 2026 abstract reports pooled results from INSPIRE 1 and INSPIRE 2. Across 806 participants, 38.8% receiving tildrakizumab, Ilumya's active ingredient, met the ACR20 response criterion at week 24, compared with 24.4% receiving placebo.
That is a 14.4 percentage-point difference, or about 14 additional responders per 100 treated under those trial conditions. ACR20 requires at least 20% improvement in specified arthritis response measures. It does not mean remission or that every symptom improved by the same amount.
The studies included people with prior anti-TNF treatment experience and people without it. Participants received study treatment at weeks 0 and 12. The abstract reports stronger joint and skin responses on several measures, but the difference on the HAQ Disability Index measure of physical function was not statistically significant. It also describes its statistical tests as nominal. The abstract is scheduled for a November 10 poster session; that presentation has not yet occurred.
The label reports results for the individual trials. Their placebo comparisons cannot support a ranking against another biologic or predict one person's outcome.
Risks to review before treatment
The prescribing information warns about infection and serious allergic reactions. It calls for tuberculosis evaluation before treatment and avoiding live vaccines during treatment. In the pooled psoriatic arthritis safety data, infections occurred in 31% of Ilumya recipients and 28% of placebo recipients over 24 weeks; serious infections occurred in 0.4% and 0%, respectively.
Where another option fits
The American College of Rheumatology's patient guidance explains that psoriatic arthritis can affect joints even when the skin disease is not the most prominent problem. Treatment aims to reduce inflammation and prevent lasting joint damage. Existing choices include conventional disease-modifying drugs, biologics and oral medicines, selected according to disease severity and the patient's circumstances.
For someone considering Ilumya, the immediate discussion is whether its provider-administered schedule suits their care, how the joint and skin symptoms will be assessed, and how infection history affects the choice. Patients taking an existing prescription should review any change with their treating clinician.
